What's Happening?
Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company, has announced a new agreement with a U.S.-based cGMP manufacturer to produce its lead compound, PH-762. This drug is being developed as an intratumoral therapy for cutaneous carcinomas,
utilizing Phio's proprietary INTASYL® gene silencing technology. The agreement marks a significant step in advancing PH-762 for both clinical trials and potential commercial supply. In recent trials, PH-762 has shown promising results, with a 65% pathological response rate in cutaneous squamous cell carcinoma (cSCC) patients, including an 85% response in the highest-dose cohort. The company plans to engage with the FDA for further clinical development in the second quarter of 2026.
Why It's Important?
This development is crucial for Phio Pharmaceuticals as it strengthens its position in the competitive field of cancer therapeutics. By securing a U.S. manufacturing partner, Phio not only ensures a reliable supply chain for its clinical trials but also aligns with strategic advantages of domestic production. The promising trial results of PH-762 could potentially lead to a non-surgical treatment option for skin cancers, addressing a significant unmet medical need. This could have substantial implications for patients and healthcare providers, offering a new avenue for treatment that could improve patient outcomes and reduce the need for invasive procedures.
What's Next?
Phio Pharmaceuticals is preparing for further engagement with the FDA to discuss the next stages of clinical development for PH-762. The company is also focused on sustaining its operations with projected cash reserves into the first half of 2027. As the clinical trials progress, Phio will likely seek additional partnerships or funding to support the commercialization of PH-762, should it receive regulatory approval. The outcomes of these engagements and trials will be pivotal in determining the drug's future in the market.
